ICU Medical Inc ICUI

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

• The Motley Fool 16 sept

  ICU Medical CFO Brian Bonnell Sells 9,307 Shares

  ICU Medical CFO Brian Bonnell sold 9,307 shares on August 31, 2026, through a pre-planned Rule 10b5-1 trading plan established in June 2026. The sale, valued at $1.6 million, is not considered a red flag as it was scheduled in advance and Bonnell retains 62,443 shares worth $10.8 million. Analysts remain bullish on the stock with an 88% buy rating and a median price target of $195.

  

• GlobeNewswire Inc. 7 sept

  Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA

  The global drug reconstitution systems market is expected to grow at a 7.0% CAGR from $5.9 billion in 2026 to $10.8 billion by 2035, driven by expanding biologic and biosimilar pipelines, increasing demand for safer drug delivery systems, and the shift toward home healthcare and self-administered therapies. Cartridges lead the market at 50% revenue share, while prefilled syringes are expected to grow faster. Asia-Pacific is projected to achieve the fastest regional growth.

  

• The Motley Fool 10 jun

  ICU Medical's General Counsel Sells — The Smiths Integration Is Almost Done, the Proof Isn'tICU Medical's General Counsel Sells — The Smiths Integration Is still playing out.

  ICU Medical's General Counsel Ruth Sanzone sold 2,447 shares worth ~$304,000 in an open-market transaction. While the Smiths Medical integration nears completion with manufacturing consolidation largely finished, the company faces headwinds from ~$1 billion in net debt, tariff pressures of $40-50 million annually, and a stock down 16% over the past year. The company's ability to achieve its 43% gross margin target and 2x leverage goal remains unproven after three years.